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Background 
Traditional pathological assessment of tissue sections involves subjective analysis of complex and 
heterogeneous features, typified by the challenge of ‘measuring’ PD-L1 expression in non-small cell 
lung cancer (NSCLC) as a guide to its treatment with immune checkpoint inhibitors. Such 
heterogeneity is generally perceived as a problem but might, in fact, reflect not only biologically 
important epitope variation, but also important features of the tumour microenvironment and, by 
extension, be a tool for predicting behaviour. In-depth analysis of a single slide of a tumour by digital 
pathology, image analysis and machine learning makes more accurate and meaningful analysis a 
possibility. 
Method 
Expression of PD-L1 was assessed by immunochemistry in 250 sections from 137 resected NSCLCs 
using the Ventana SP263 antibody and a validated protocol and its distribution compared with 
morphology as revealed by corresponding HandE-stained sections. Slides were scanned to create a 
digital image using Aperio Scanscope with division of images into 1mm2 squares using QuPath 
opensource software, each of which was assigned x and y co-ordinates. Squares were assessed 
subjectively by two pathologists for morphological features and PD-L1 expression and also subject to 
automatic image analysis including cell counting and membrane detection. Co-ordinates and values 
were stored in Microsoft Excel and a digital database was generated for every slide. In-depth 
analysis of digital data points was achieved using “R” software custom algorithms that included 
simulating biopsy sampling and applying spatial analysis packages. 
Result 
The resulting database, comprising approximately 30,000 data points from the 137 tumours, is being 
used to simulate needle-core biopsies, assess heterogeneity of PD-L1 expression and relate this to 
the tumour micro-environment including immune cell populations, immune signature and tumour 
mutational burden. 
Conclusion 
The vast amount of information in every NSCLC cannot be extracted by conventional 
histopathological analysis. By utilising new technologies and considering alternative paradigms for 
data acquisition, powerful new approaches may be developed that give information pertaining to 
not just diagnostic and prognostic features of a tumour, but behavioural traits including likely 
responses and resistances to novel drugs such as immune checkpoint inhibitors. The methodology 
described here is an attempt to extract these data in a more objective way and complement the still 
crucial subjective analysis that is traditionally the prerogative of the histopathologist. 
